Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7% – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares fell 7% during trading on Thursday . The company traded as low as $19.08 and last traded at $19.4350. 4,313 shares were traded during trading, an increase of 9% from the average session volume of 3,955 shares. The stock had previously closed at $20.90.

Analyst Upgrades and Downgrades

Several analysts have commented on AAPG shares. BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Down 2.4%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company’s 50 day simple moving average is $23.23 and its 200 day simple moving average is $25.90.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter. On average, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently made changes to their positions in AAPG. XY Capital Ltd increased its position in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the second quarter worth $391,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Finally, ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.